CN117460528A - 抗cldn18.2抗体缀合物 - Google Patents

抗cldn18.2抗体缀合物 Download PDF

Info

Publication number
CN117460528A
CN117460528A CN202280015857.3A CN202280015857A CN117460528A CN 117460528 A CN117460528 A CN 117460528A CN 202280015857 A CN202280015857 A CN 202280015857A CN 117460528 A CN117460528 A CN 117460528A
Authority
CN
China
Prior art keywords
seq
sequence
cldn
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280015857.3A
Other languages
English (en)
Chinese (zh)
Inventor
钱雪明
朱华
滕菲
李红俊
杨志
顾怡
丁缙
王风
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Chuangsheng Pharmaceutical Group Co ltd
Peking University Cancer Hospital
Original Assignee
Suzhou Chuangsheng Pharmaceutical Group Co ltd
Peking University Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Chuangsheng Pharmaceutical Group Co ltd, Peking University Cancer Hospital filed Critical Suzhou Chuangsheng Pharmaceutical Group Co ltd
Publication of CN117460528A publication Critical patent/CN117460528A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280015857.3A 2021-02-19 2022-02-18 抗cldn18.2抗体缀合物 Pending CN117460528A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021076910 2021-02-19
CNPCT/CN2021/076910 2021-02-19
CNPCT/CN2022/074750 2022-01-28
CN2022074750 2022-01-28
PCT/CN2022/076810 WO2022174809A1 (en) 2021-02-19 2022-02-18 Anti-cldn18.2 antibody conjugates

Publications (1)

Publication Number Publication Date
CN117460528A true CN117460528A (zh) 2024-01-26

Family

ID=82932096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280015857.3A Pending CN117460528A (zh) 2021-02-19 2022-02-18 抗cldn18.2抗体缀合物

Country Status (9)

Country Link
US (1) US20240307564A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294441A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511281A (cg-RX-API-DMAC7.html)
KR (1) KR20230146623A (cg-RX-API-DMAC7.html)
CN (1) CN117460528A (cg-RX-API-DMAC7.html)
AU (1) AU2022223150A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211403A1 (cg-RX-API-DMAC7.html)
TW (1) TW202302153A (cg-RX-API-DMAC7.html)
WO (1) WO2022174809A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120091830A (zh) * 2022-08-24 2025-06-03 苏州创胜医药集团有限公司 使用抗cldn18.2抗体-放射性核素缀合物的非侵入性方法
KR20240176948A (ko) * 2023-06-15 2024-12-26 에이비온 주식회사 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도
JP2025005493A (ja) * 2023-06-28 2025-01-17 Jfeエンジニアリング株式会社 放射性治療薬による治療効果を確認する方法
KR20250062080A (ko) 2023-10-30 2025-05-08 주식회사 엘지에너지솔루션 배터리 데이터 수집 서버 및 이의 동작 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2852409B1 (en) * 2012-05-23 2020-03-25 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2018321893A1 (en) * 2017-08-23 2020-03-19 Wayne State University In vivo immunoimaging of interferon-gamma
CA3087423A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
BR112021002032A2 (pt) * 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
BR112021023024A2 (pt) * 2019-05-16 2022-01-25 Qilu Pharmaceutical Co Ltd Anticorpo contra claudina 18a2 e uso do mesmo
CA3141504A1 (en) * 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
CN114630840B (zh) * 2019-08-20 2024-08-02 苏州创胜医药集团有限公司 新型抗cldn18.2抗体
CN111777681B (zh) * 2020-07-06 2022-10-11 康诺亚生物医药科技(成都)有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途

Also Published As

Publication number Publication date
AU2022223150A1 (en) 2023-09-21
US20240307564A1 (en) 2024-09-19
KR20230146623A (ko) 2023-10-19
EP4294441A1 (en) 2023-12-27
AU2022223150A9 (en) 2024-01-04
JP2024511281A (ja) 2024-03-13
WO2022174809A1 (en) 2022-08-25
EP4294441A4 (en) 2026-03-25
CA3211403A1 (en) 2022-08-25
TW202302153A (zh) 2023-01-16

Similar Documents

Publication Publication Date Title
ES3061799T3 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
WO2022174809A1 (en) Anti-cldn18.2 antibody conjugates
JP6970017B2 (ja) ヒトa33抗原とdota金属複合体に親和性を有する多重特異性抗体及びその使用
KR20220057517A (ko) 신생아 fc 수용체에 대한 감소된 친화성을 갖는 psma 결합을 위한 항체
KR101820029B1 (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
US20250073359A1 (en) Radiolabeled biomolecules and their use
ES2460945T3 (es) Un anticuerpo monoclonal para CD44 para su uso en el tratamiento de carcinoma de células escamosas de cabeza y cuello
JP2017532952A (ja) 抗体、組成物および使用
US20230340111A1 (en) Antibody fragment against folr1
KR20220057516A (ko) 신생아 fc 수용체에 대한 친화도가 감소된 caix에 대한 항체
US20200197547A1 (en) Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers
WO2024041574A1 (en) Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates
EP4662244A1 (en) Anti-mesothelin nanobodies, constructs and conjugates
HK40106087A (en) Anti-cldn18.2 antibody conjugates
AU2024320882A1 (en) Trophoblast glycoprotein antibody compositions and methods of use
US20230190968A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2025207904A1 (en) Psma radiopharmaceutical conjugate and uses thereof
WO2025040588A1 (en) Monoclonal anti-ptk7 antibodies and derivatives
EA052523B1 (ru) Антитела против cd44v6 и их использование для лечения онкологических заболеваний, характеризующихся гиперэкспрессией cd44v6

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106087

Country of ref document: HK